Given the alterations observed following ALDH2-KO in melanoma cells, such as activation of the MAPK/ERK pathway, enhanced inflammatory phenotypes, and a metabolic shift towards glycolysis, we examined how ALDH2 status influences the sensitivity of melanoma cells to MAPK/ERK inhibitors. The gene discussed is ALDH2; the disease is melanoma.